Rheumatology最新文献

{"title":"Comparison of quantitative lung ultrasound scores with automated quantitative CT: to overcome the ultrasound limitations.","authors":"Davide Mohammad Reza Beigi, Greta Pellegrino, Nicholas Landini, Marco Emanuele Diana, Gregorino Paone, Ilaria Bisconti, Francesca Romana Di Ciommo, Marius Cadar, Elena Platania, Jacopo Landro, Simona Truglia, Valeria Panebianco, Fabrizio Conti, Valeria Riccieri","doi":"10.1093/rheumatology/keaf328","DOIUrl":"https://doi.org/10.1093/rheumatology/keaf328","url":null,"abstract":"<p><strong>Objectives: </strong>Lung ultrasound (LUS) is emerging as a valuable tool for assessing systemic sclerosis-associated interstitial lung disease (SSc-ILD), although it traditionally explores only superficial lung regions. Building upon our preliminary findings, this study investigated correlations between quantitative LUS scores and automated quantitative computed tomography (qCT) measurement of ILD extent, including both superficial and deeper lung involvement.</p><p><strong>Methods: </strong>Between 2021 and 2023, 82 consecutive SSc patients underwent concurrent LUS and CT scans. Total B-lines (BL) count (range 0-140) and our novel pleural line irregularity (PLI) score (range 0-28) were obtained using a 14-intercostal space scanning protocol. CT scans were analysed by automated texture analysis software, quantifying volumes of ILD, ground-glass opacities (GGO) and reticulations (RET), segmented in three levels (apices, midfields, bases) and subdivided in surface and core lung parenchyma.</p><p><strong>Results: </strong>Total BL count and PLI score correlated with total ILD, GGO and RET volumes (all p< 0.0001), as well as with surface and core ILD volumes (all p< 0.0001). Basal lung BLs and PLI score correlated with basal ILD, GGO, RET (all p< 0.005), and corresponding surface and core ILD volumes (all p< 0.005). Mid-lung PLI correlated also with corresponding ILD-related changes and surface and core ILD (all p< 0.005). These associations were confirmed by multivariate regression analysis.</p><p><strong>Conclusions: </strong>Quantitative LUS score correlated with qCT-defined ILD extent, especially at lung bases. LUS scores (particularly the novel PLI score) were found to correlate with deeper ILD volume, suggesting potential to overcome traditional LUS limitations related to superficial lung assessment.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144275760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Executive summary: The 2025 British Society for Rheumatology management recommendations for ANCA-associated vasculitis.","authors":"Kathryn Biddle, Judith Jade, Harold Wilson-Morkeh, Madura Adikari, Chadwan Al Yaghchi, Zoi Anastasa, Neil Basu, Paul Brogan, Dimitrios Chanouzas, Shouvik Dass, David D'Cruz, Marcos Martinez Del Pero, Emmandeep Dhillon, Georgina Ducker, Siân Griffin, Rosemary J Hollick, David Jackson, Catherine King, Matko Marlais, Alice Mason, Stephen McAdoo, Devesh Mewar, Janice Mooney, Eleana Ntatsaki, Fiona Pearce, Benjamin Rhodes, Hitasha Rupani, Alan Salama, Salman Siddiqui, Rona Smith, Lorraine Harper","doi":"10.1093/rheumatology/keaf242","DOIUrl":"https://doi.org/10.1093/rheumatology/keaf242","url":null,"abstract":"","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144275761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baricitinib in rheumatoid arthritis-interstitial lung disease: national multicenter study of 72 patients and literature review.","authors":"Ana Serrano-Combarro, Belén Atienza-Mateo, Adrián Martín-Gutiérrez, Jesús Loarce Martos, César Antonio Egües Dubuc, Marta Pastor Mena, Rafael B Melero-Gonzalez, María Martín López, Natalia Mena Vázquez, Carmen Carrasco-Cubero, Carolina Pérez García, Andrea García Valle, Gema Bonilla, Juan María Blanco Madrigal, Uxue Astigarraga-Urquia, Nuria Vegas Revenga, Lorena Pérez Albadalejo, Rafaela Ortega Castro, Deseada Palma Sánchez, Ana María Fernández Ortiz, Patricia López Viejo, María López Lasanta, Marta Garijo Bufort, Ivette Casafont Solé, José Ramón Lamua-Riazuelo, Ignacio Braña Abascal, Virginia Ruiz-Esquide, Evelin Cervantes Perez, Bryan-Josué Flores Robles, María Paz Martínez-Vidal, Juan Moreno Morales, Ana Urruticoechea-Arana, José Rosas, Delia Fernández Lozano, David Castro Corredor, Iván Ferraz-Amaro, Santos Castañeda, Ricardo Blanco","doi":"10.1093/rheumatology/keaf314","DOIUrl":"https://doi.org/10.1093/rheumatology/keaf314","url":null,"abstract":"<p><strong>Objective: </strong>To assess the effectiveness and safety of baricitinib (BARI) in Rheumatoid Arthritis-interstitial lung disease (RA-ILD) in clinical practice.</p><p><strong>Methods: </strong>: National multicentre retrospective study of 72 RA-ILD patients treated with BARI. We analyzed the following outcomes at baseline and at 3, 6, 12, 18, 24 months, and last follow-up: a) dyspnea (modified Medical Research Council scale), b) forced vital capacity (FVC), c) diffusing capacity of the lungs for carbon monoxide (DLCO), d) chest high resolution computed tomography (HRCT), e) arthritis activity (DAS28-ESR), and f) corticosteroid-sparing effect. Additionally, we analyzed safety data and performed a literature review up to now.</p><p><strong>Results: </strong>We included 72 patients (52 women; mean age 68 ± 10 years). All patients had received disease-modifying antirheumatic drugs (DMARDs). Median ILD duration up to BARI initiation was of 25 [13-63] months. Most frequent ILD patterns were usual interstitial pneumonia (n = 33; 49%) and non-specific interstitial pneumonia (n = 22; 32%). BARI was used in monotherapy in 43 (60%) patients and combined with conventional DMARDs in 29 (40%). Mean baseline values of FVC and DLCO (% pred.) were 86 ± 28 and 69 ± 20, respectively. After a median [IQR] follow-up of 32 [13-65] months dyspnea, FVC, DLCO, HRCT improved/stabilized in 90%, 88%, 65%, 72%, respectively. Mean DAS28-ESR improved from 4.29-2.99. and median prednisone dose was reduced from 5 to 2.5 mg/day. Relevant adverse events were uncommon.</p><p><strong>Conclusion: </strong>BARI may be a useful and safe alternative in both pulmonary and joint disease in RA-ILD patients, even in refractory cases.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144267149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognosis of essential mixed cryoglobulinemia and connective tissue disease-related cryoglobulinemia after rituximab-induced remission","authors":"Claire Poggi, Eric Hachulla, Alexandre Karras, Antoine Briantais, Camille Ravaiau, Pierre Gobert, Alban Deroux, Sarah Nicolas, Nabil Belfeki, Hélène François, Matthieu Groh, Jonathan London, Julien Campagne, Jean-Sébastien Allain, Emmanuelle Dernis, Cécile-Audrey Durel, Thomas Le Gallou, Alexandre Curie, Philippe Kerschen, Noémie Gensous, Anne-Hélène Reboux, Hélène Béhal, Benjamin Terrier, Thomas Quéméneur","doi":"10.1093/rheumatology/keaf324","DOIUrl":"https://doi.org/10.1093/rheumatology/keaf324","url":null,"abstract":"Objectives Rituximab (RTX) and glucocorticoids are the first line treatment for essential (EM) and connective tissue disease (CTD)-related mixed cryoglobulinemia vasculitis (CryoVas). Data on long term outcomes of these CryoVas are lacking. We aimed to describe the prognosis of patients with EM and CTD-related CryoVas. Methods We conducted a retrospective study on patients with EM or CTD-related CryoVas in remission after RTX-based therapy. Results We included 63 patients with a median follow-up of 58 months (IQR, 33–88 months). Relapse rates were 23% at 1 year, 42% at 2 years and 71% at 5 years after the initial flare. In univariate analysis, factors associated with relapse were purpura (HR, 2.2; 95% confidence interval (CI), 1.1–4.4; p = 0.02) and a previous flare of CryoVas (HR, 1.9; 95% CI, 1.0–3.7; p = 0.04). Maintenance therapy was associated with a lower risk of early relapse (HR, 0.3; 95% CI, 0.1–0.9; p = 0.03), but not of late relapse (HR, 2.0; 95% CI, 0.7–5.7; p = 0.21). In multivariable analysis, patients without purpura or previous flare remained at lower risk of relapse than those with at least one of the two (HR, 3.6; 95%CI, 1.6–8.2; p= 0.002). Maintenance regimen was associated with a lower risk of early relapse (HR, 0.3; 95% CI, 0.1–0.9; p = 0.03). Conclusion In patients with EM and CTD-related CryoVas who received RTX as induction therapy, relapses were frequent and associated with purpura and a previous flare, but were reduced with maintenance therapy.","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":"145 1","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144259970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case-control study on autoimmune polyendocrine syndromes in patients with systemic lupus erythematosus","authors":"Elda Piovani, Giorgia Gozzoli, Silvia Della Pina, Claudia Barison, Chiara Orlandi, Elisa Gatta, Cesare Tomasi, Micaela Fredi, Carlo Cappelli, Franco Franceschini","doi":"10.1093/rheumatology/keaf320","DOIUrl":"https://doi.org/10.1093/rheumatology/keaf320","url":null,"abstract":"Objectives This study aimed to investigate the prevalence of Autoimmune Polyendocrine Syndromes (APS) in patients with Systemic Lupus Erythematosus (SLE) and to assess whether APS predicts higher disease activity or worse outcomes. Methods Clinical charts of 417 SLE patients, meeting SLICC 2012 and/or EULAR/ACR 2019 criteria, referring to our Centre between 2021 and 2023 were analysed. APS cases were identified using ORPHA definitions; 185 APS-free SLE patients, randomly enrolled, served as controls. Demographic, clinical and serological data were collected. Results Forty-seven of 417 (11%) SLE patients had another autoimmune disease affecting the glands that allows the diagnosis of APS: 39 were diagnosed with Hashimoto thyroiditis, 6 with Graves’ disease, and 3 with type 1 diabetes mellitus. Forty-five were affected by APS type 3, and 2 by APS type 4; no patients were diagnosed with APS 1 or 2. The comparison between APS+ and APS- patients revealed no significant differences in clinical or serological features. At the last evaluation, ∼80% of both groups’ patients were in clinical remission and approximately half of the patients remained on steroid therapy. APS+ patients had a slightly higher median damage index (SLICC-SDI), although this was not associated with increased disease activity. Conclusion The prevalence of APS among SLE patients is significantly higher than in the general population (11% vs 0,005%), confirming the association between autoimmune thyroiditis and SLE. However, APS+ patients do not appear to have a more aggressive disease or develop more complications.","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":"1 1","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144260082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When to address fatigue in juvenile idiopathic arthritis during clinical visits based on the JAMAR","authors":"Anouk Vroegindeweij, S A Musterd, Sanne L Nijhof, Alessandro Consolaro, Sebastiaan J Vastert, Sytze De Roock, Joost F Swart","doi":"10.1093/rheumatology/keaf325","DOIUrl":"https://doi.org/10.1093/rheumatology/keaf325","url":null,"abstract":"Objectives Fatigue is a prevalent but overlooked issue among patients with Juvenile Idiopathic Arthritis (JIA) in clinical practice. The internationally widely used Juvenile Arthritis Multidimensional Assessment Report (JAMAR) does not include items on fatigue. We evaluated whether items from its Quality of Life (QoL) section could be used as proxy measurement for fatigue, prompting practitioners to address issues with fatigue during a clinical visit. Methods 105 JIA patients at the Wilhelmina Children’s Hospital (WCH) completed the JAMAR and Checklist Individual Strength-8 (CIS-8), a questionnaire with validated cut-off score for severe fatigue in rheumatic conditions. Correlations were inspected to test whether QoL items 3 (difficulty with energy-demanding activities) and 9 (concentration or attention issues) correlated strongest with severe fatigue. With binary logistic regressions and ROC analyses, the proxy’s predictive value and cut-off were determined. The proxy was re-used in the EPOCA cohort for comparison. Results The proposed items showed the strongest correlation with severe fatigue (ritem3=0.644 and ritem9=0.565). Their sum score represented the proxy (range 0–6). The proxy was a significant predictor of severe fatigue controlled for age, sex, and disease activity (p&amp;lt;0.001). Area Under the Curve was 0.911, sensitivity 90% and specificity 69.6% with cut-off score ≥1. According to the proxy, fatigue should be addressed in 58.1% of WCH patients and in 56.6% of the EPOCA cohort. Conclusion The proxy can be used to estimate whether issues with fatigue should be explored during clinical visits. To quantify fatigue severity levels, we recommend using the CIS-8 or another fatigue questionnaire.","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":"6 1","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144252355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disease modifying anti-rheumatic drug treatment cycles and rates of flare in juvenile idiopathic arthritis—a tale of Sisyphean endeavour?","authors":"Emily Bugeja, Georgina Tiller, William Renton, Jane Munro, Peter Gowdie, Angela Cox, Roger Allen, Jo Buckle, Jonathan Akikusa","doi":"10.1093/rheumatology/keaf321","DOIUrl":"https://doi.org/10.1093/rheumatology/keaf321","url":null,"abstract":"Objectives Withdrawal of Disease Modifying Antirheumatic Drugs (DMARDs) to determine need for ongoing medication is common in JIA management. Little is known about how often patients undergo trials of medication discontinuation or the outcomes of successive trials. This study examined DMARD treatment cycles in a JIA cohort to determine how frequently medication withdrawal trials occur over follow-up and if relapse rates change over consecutive cycles. Methods Retrospective review of longitudinal cohort data of children with DMARD-treated JIA diagnosed between 2010–14. Extracted data included demographics, DMARD therapy details and clinical assessments including active joint count, date of last follow-up and disease status at that time. Data was collected to January 2024. Results Ninety-one children were studied. Median age 10.1 yr (range 1.5–16.8), 59% were female and median follow-up 7.0 yr (range 0.7–13). A maximum of 4 cycles of DMARD treatment were undertaken. 44.0% of children underwent more than one cycle. 63.5% relapsed after their first cycle and 53.3% after their second. 25.3% remained off treatment to last follow-up following cycle one and over two subsequent cycles of therapy this increased to just 35.2%. Conclusion In JIA patients requiring DMARD therapy recurrent treatment withdrawal trials are common over follow-up, but relapse risk is high and remains so over successive trials. Permanent treatment withdrawal is therefore not a realistic goal for most patients with therapies currently available. Until biomarkers of permanent remission are developed, strategies to minimize both drug toxicity and the risk of disease flares in patients with recurrently active disease after medication withdrawal are required.","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":"20 1","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144252356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Automated detection of spinal bone marrow oedema in axial spondyloarthritis: training and validation using two large phase 3 trial datasets","authors":"Amir Jamaludin, Rhydian Windsor, Sarim Ather, Timor Kadir, Andrew Zisserman, Juergen Braun, Lianne S Gensler, Mikkel Østergaard, Denis Poddubnyy, Thibaud Coroller, Brian Porter, Gregory Ligozio, Aimee Readie, Pedro M Machado","doi":"10.1093/rheumatology/keaf323","DOIUrl":"https://doi.org/10.1093/rheumatology/keaf323","url":null,"abstract":"Objective To evaluate the performance of machine learning (ML) models for the automated scoring of spinal MRI bone marrow oedema (BMO) in patients with axial spondyloarthritis (axSpA) and compare them with expert scoring. Methods ML algorithms using SpineNet software were trained and validated on 3483 spinal MRIs from 686 axSpA patients across two clinical trial datasets. The scoring pipeline involved (i) detection and labelling of vertebral bodies and (ii) classification of vertebral units for the presence or absence of BMO. Two models were tested: Model 1, without manual segmentation, and Model 2, incorporating an intermediate manual segmentation step. Model outputs were compared with those of human experts using kappa statistics, balanced accuracy, sensitivity, specificity, and AUC. Results Both models performed comparably to expert readers, regarding presence vs absence of BMO. Model 1 outperformed Model 2, with an AUC of 0.94 (vs 0.88), accuracy of 75.8% (vs 70.5%), and kappa of 0.50 (vs 0.31), using absolute reader consensus scoring as the external reference; this performance was similar to the expert inter-reader accuracy of 76.8% and kappa of 0.47, in a radiographic axSpA dataset. In a non-radiographic axSpA dataset, Model 1 achieved an AUC of 0.97 (vs 0.91 for Model 2), accuracy of 74.6% (vs 70%), and kappa of 0.52 (vs 0.27), comparable to the expert inter-reader accuracy of 74.2% and kappa of 0.46. Conclusion ML software shows potential for automated MRI BMO assessment in axSpA, offering benefits such as improved consistency, reduced labour costs, and minimised inter- and intra-reader variability. Trial registration Clinicaltrials.gov, MEASURE 1 study (NCT01358175); PREVENT study (NCT02696031)","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":"36 1","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144252354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep and circadian parameters in Behçet's syndrome: a comparative analysis using actigraphy and questionnaires","authors":"Alessandro Colitta, Simone Bruno, Francy Cruz-Sanabria, Federico Starace, Andrea Bazzani, Federica Di Cianni, Paolo Frumento, Michelangelo Maestri Tassoni, Enrica Bonanni, Marta Mosca, Rosaria Talarico, Ugo Faraguna","doi":"10.1093/rheumatology/keaf326","DOIUrl":"https://doi.org/10.1093/rheumatology/keaf326","url":null,"abstract":"OBJECTIVE Sleep disturbances are highly prevalent in Behçet Syndrome (BS) patients. Within this population, sleep disturbances are frequently associated with active disease and comorbid fibromyalgia. However, possible sleep impairments in BS patients without these conditions remain poorly explored, along with BS patients’ obstructive sleep apnea (OSAS) risk and circadian rhythm preferences. We aimed to address these research gaps through a cross-sectional study comparing sleep and circadian parameters between BS patients, with or without active disease and comorbid fibromyalgia, and healthy controls (HCs). METHODS Participants’ sleep and circadian parameters were evaluated objectively via actigraphy and subjectively through the Pittsburgh Sleep Quality Index and the reduced Morningness-Eveningness Questionnaire. A comprehensive clinical evaluation investigated sociodemographic data, disease activity and comorbid fibromyalgia. Possible predictors of sleep and circadian parameters were tested estimating linear regression models. RESULTS 45 BS patients and 61 age-, BMI-, sex-, and smoking habits-matched HCs were enrolled. Only BS patients with active disease and/or fibromyalgia showed significantly lower sleep quality, significantly higher sleep fragmentation, and a tendence towards less robust circadian rhythms compared to other participants. Instead, BS patients without those conditions did not significantly differ from HCs in sleep and circadian parameters. Furthermore, a higher actigraphically-determined OSAS risk was found in all BS patients compared to HCs. CONCLUSIONS Active disease and fibromyalgia are associated with sleep and circadian rhythm disturbances in BS patients. Screening for sleep and circadian rhythm disturbances may be advised in BS patients with these conditions, while OSAS screening may be recommended in all BS patients with sleep disturbances.","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":"18 1","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144252410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving preventive health in inflammatory rheumatic diseases: A randomized controlled trial of an educational video intervention","authors":"Vanessa Bartsch, Basel Habboub, Kathrin Standfest, Mathias Ausserwinkler, Johannes Knitza, Georg Schett, Axel J Hueber","doi":"10.1093/rheumatology/keaf316","DOIUrl":"https://doi.org/10.1093/rheumatology/keaf316","url":null,"abstract":"Objective To evaluate the impact of an educational video on adherence to preventive health measures in patients with inflammatory rheumatic diseases. Methods The KOMO-R study was a prospective, six-month, single-center, randomized controlled trial. Participants received personalized to-do lists with up to 13 tasks based on local preventive health guidelines. The intervention group additionally watched a seven-minute educational video on rheumatic comorbidities. The primary outcome was the number of tasks completed from the to-do lists. Results Of 199 participants, 182 attended the six-month follow-up. The video received a Net Promoter Score of 39.4%. 79.8% of the intervention group reported increased perceived importance of preventive health services after watching the video. Task completion from the to-do lists did not differ between intervention and control group (p = 0.59). Participants completed a mean of 2.6 ± 1.9 tasks (62.5% of tasks on their to-do lists, control 61.5%, intervention 63.3%). At 6-month follow-up, significant increases were seen in all preventive health measures, including screenings for skin cancer (Δ27.8%, p &amp;lt; 0.001), prostate cancer (Δ21.6%, p = 0.003), colorectal cancer (Δ13%, p &amp;lt; 0.001), and gynecological cancers (p &amp;lt; 0.05). Vaccination rates also improved significantly, including pneumococcal (Δ23.5%), influenza (Δ13.2%), and herpes zoster (Δ4.1%) (all p &amp;lt; 0.001). Conclusion Although the educational video was well-received and increased the perceived importance of preventive health, it showed no added benefit in improving adherence to preventive health measures. Further research is needed to explore the potential of to-do lists in preventive care as to-do lists significantly increased adherence.","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":"20 1","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144237048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}